ImmunityBio Investors Alert: Kirby McInerney LLP Files Securities Class Action Lawsuit

A securities class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. securities during the period of January 19, 2026 through March 24, 2026. The lawsuit alleges that defendant Patrick Soon-Shiong overstated the capabilities of Anktiva, an FDA-approved cancer treatment, in public statements. The FDA issued a warning letter to ImmunityBio on March 24, 2026, stating that Anktiva's promotional materials were false or misleading. The price of ImmunityBio shares declined by 21.2% following the news. Investors who acquired ImmunityBio securities during the class period have until May 26, 2026 to request lead plaintiff appointment.